Tarceva (erlotinib) — United Healthcare
Pancreatic Cancer
Initial criteria
- Diagnosis pancreatic cancer
- Disease is one of the following: locally advanced OR unresectable OR metastatic
- Used in combination with gemcitabine
Reauthorization criteria
- Patient does not show evidence of progressive disease while on Tarceva therapy
Approval duration
12 months